Typical Patient Weight Loss Results 8 weeks, 10 15 lbs 12 weeks, 15 25 lbs 16 weeks, 25 35 lbs 20 weeks, 35+ lbs Furthermore, almost a third of patients lost 20% of their total body weight
It is a glucagon-like peptide-1 (GLP-1) receptor agonist and works by increasing insulin secretion from the beta cells in the pancreas
These data, showing a 23% risk reduction of a heart attack, stroke and death, fill an important gap and reinforce the well-established clinical evidence of semaglutide
Secondly, Semaglutide slows down the emptying of the stomach
Wegovy is indicated for adults with BMI 30 kg/m or 27 kg/m with at least one weight-related condition, and for adolescents aged 12 and older with BMI 95th percentile for age and sex